Exelixis (EXEL)
NASDAQ:EXEL
Want to see EXEL full AI Analyst Report?
EXEL Stock Chart & Stats
$44.89
$0.17(0.50%)
At close: 4:00 PM EST
$44.89
$0.17(0.50%)
Day’s Range― - ―
52-Week Range$33.76 - $53.93
Previous CloseN/A
Volume463.09K
Average Volume (3M)2.74M
Market Cap
$13.35B
Enterprise Value$12.63B
Total Cash (Recent Filing)$777.21M
Total Debt (Recent Filing)$169.54M
Price to Earnings (P/E)16.5
Beta0.89
Next Earnings
Aug 05, 2026EPS Estimate
0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.12
Shares Outstanding251,355,090
10 Day Avg. Volume2,324,126
30 Day Avg. Volume2,740,739
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)5.48
Price to Sales (P/S)5.10
P/FCF Ratio14.02
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue5.32
Enterprise Value/Gross Profit5.51
Enterprise Value/Ebitda12.44
Forecast
1Y Price Target
$47.70Price Target Upside6.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)3.52
Revenue Forecast (FY)$2.60B
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistently strong operating cash flow and near‑par free cash flow convertibility provide durable funding for R&D, buybacks, and potential M&A. High cash conversion reduces refinancing risk and supports ongoing capital returns and clinical programs over the next 2–6 months.
High ProfitabilityVery high margins indicate a capital‑efficient business model and pricing power in its specialty oncology franchise. Sustained profitability supports reinvestment in pivotal trials and steady operating leverage, improving resilience to uneven revenue quarters common in biotech.
Commercial Franchise MomentumEscalating prescription volumes and market share gains for CABOMETYX reflect durable competitive positioning in the oral TKI market. A growing installed base and expanding first‑line share underpin sustained revenue potential and de‑risk near‑term commercialization of follow‑on indications.
Bears Say
Rising Gross‑to‑net DeductionsHigher gross‑to‑net reduces net realized product revenue and can persist if payer mix or assistance programs continue. Over time this compresses cash receipts and effective price per unit, limiting upside from volume gains and pressuring margin sustainability.
Dependence On Pivotal ReadoutsMultiple upcoming pivotal results and regulatory decisions create structural binary risk for material growth beyond CABOMETYX. Delays or unfavorable outcomes would curtail expansion plans and strain the growth profile, affecting multi‑indication commercialization timelines.
Revenue Lumpiness & ConcentrationHeavy reliance on a single franchise leads to lumpy, year‑to‑year revenue and exposes the company to market access shifts. Such concentration raises execution risk for sustaining top‑line growth absent timely pipeline diversifications or additional durable revenue sources.
Exelixis News
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $33.76 and its highest was $53.93 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $13.35B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Aug 05, 2026 which is in 50 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on May 05, 2026. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.765 by $0.105.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.85.
How many shares outstanding does Exelixis have?
Exelixis has 251,355,090 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.87 in its last earnings report, beating expectations of $0.765. Following the earnings report the stock price went up 9.635%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in EXEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.70 (6.26% Upside)
$47.70 (6.26% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.16%
12-Months-Change
Fundamentals
Return on Equity
40.21%
Trailing 12-Months
Asset Growth
-8.59%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
EXEL Company Deck
EXEL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for CABOMETYX (double-digit global growth, notable TRx and market share gains), solid profitability and cash position, active share repurchases, and substantial advancement of ZANZA with one positive pivotal result (20% OS risk reduction in STELLAR-303 ITT) and multiple ongoing pivotal trials across tumor types. Offsetting these positives were increased gross-to-net deductions (30.2%), a materially higher tax provision, reliance on several upcoming readouts (some immature or timing‑sensitive), and broader development complexity highlighted by a competitive miss in a related triplet program. On balance, operational and commercial strengths and a broad, advancing pipeline materially outweigh the near-term execution and regulatory uncertainties.View all EXEL earnings summariesEXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
EXEL Stock 12 Month Forecast
Average Price Target
$47.70
▲(6.26% Upside)
Technical Analysis
Ownership Overview
3.52% Insiders
26.19% Mutual Funds
23.11% Other Institutional Investors
16.92% Public Companies and
Individual Investors